Global Circulating Tumor Cell (CTC) Diagnostics Strategic Business Report 2023: Featuring ApoCell, Biocept, Fluxion Biosciences and Janssen Diagnostics Among Others

News provided by

Feb 10, 2023, 11:20 ET

DUBLIN, Feb. 10, 2023 /PRNewswire/ -- The "Circulating Tumor Cell (CTC) Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$9.1 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2022-2030.

Detection & Enrichment, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$13.8 Billion by the end of the analysis period.

Taking into account the ongoing post pandemic recovery, growth in the Analysis segment is readjusted to a revised 12.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 10.3% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 9.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Select Competitors (Total 48 Featured) -

ApoCell, Inc.
Biocep Ltd.
Biocept, Inc.
Biofluidica Microtechnologies LLC
Celltraffix Inc.
Clearbridge Biomedics
Creatv Microtech, Inc.
Cynvenio Biosystems, Inc.
Fluxion Biosciences, Inc.
Ikonisys, Inc.
IVDiagnostics, Inc.
Janssen Diagnostics LLC
QIAGEN Hannover GmbH
Rarecells Sas
Screencell
Stemcell Technologies, Inc.

What`s New for 2023?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Market Outlook
Recent Market Activity
Clinical Relevance of CTCs
CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
Major Challenges in CTC Diagnostics
Need for CTC Enrichment and Popular Methods
CTC Enrichment Techniques
Select Available CTC Detection Technologies
Select CTC Isolation Systems - A Brief Comparison
CTC Identification - Various Approaches
CTC Identification Approaches
List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
CellSearch SystemT - The First FDA Approved Automated Enrichment/Isolation Technique
Rising Incidence of Cancer - An Opportunity Indicator
Cancer Prone Sites based on Age
Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Liquid Biopsy - the New Buzzword in Healthcare
Select Companies Active in Cancer Liquid Biopsy
CTCs for Personalized Cancer Treatment
Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
CTC Microdevices Hog the Limelight
Increasing Research Reveal Further Complexities to CTC Composition and Behavior
EpCAM Glycoprotein - Insufficient for CTC Detection
New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
Physical Property-based Enrichment Technologies Lose Fizz
Evidence in Favor CTC Heterogeneity Gains Strength
CTC Clusters Raise Research Interest
Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
Limitations of CTC Technology for Point-of-Care Testing
CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
Select Research Findings in Recent Years
Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
NBiomics Makes its Contribution to CTC Diagnosis
Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
Gold Nanoparticles Help in the Detection of CTCs

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/65edwx-tumor?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets